As the world enters its third year of the COVID-19 pandemic, individuals with diabetes have faced particular challenges from the virus. A deleterious bidirectional relationship exists between the two disorders, with heightened inflammatory, immunologic, and cellular mechanisms leading to a more severe illness and increased morbidity and mortality. Tight glucose control, though necessary, is hampered by physical restrictions and difficulty accessing health care. Novel glucose-lowering medications may provide unique benefits in this regard. It is imperative that multi-pronged efforts be prioritized in order to reduce adverse outcomes in patients with diabetes at risk for COVID-19.
Stoian, A.P., Kempler, P., Stulnig, T., Rizvi, A.A., Rizzo, M. (2022). Diabetes and COVID-19: What 2 Years of the Pandemic Has Taught Us. METABOLIC SYNDROME AND RELATED DISORDERS, 20(3), 137-140 [10.1089/met.2021.0133].
Diabetes and COVID-19: What 2 Years of the Pandemic Has Taught Us
Rizzo, Manfredi
2022-04-01
Abstract
As the world enters its third year of the COVID-19 pandemic, individuals with diabetes have faced particular challenges from the virus. A deleterious bidirectional relationship exists between the two disorders, with heightened inflammatory, immunologic, and cellular mechanisms leading to a more severe illness and increased morbidity and mortality. Tight glucose control, though necessary, is hampered by physical restrictions and difficulty accessing health care. Novel glucose-lowering medications may provide unique benefits in this regard. It is imperative that multi-pronged efforts be prioritized in order to reduce adverse outcomes in patients with diabetes at risk for COVID-19.
| File | Dimensione | Formato | |
|---|---|---|---|
|
met.2021.0133.pdf
Solo gestori archvio
Tipologia:
Versione Editoriale
Dimensione
109.82 kB
Formato
Adobe PDF
|
109.82 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
